| 脑卒中与血小板活化因子及其受体拮抗剂 |
| |
| 引用本文： | 王志国,王丹巧,焦玥,田昕,孙明瑜.脑卒中与血小板活化因子及其受体拮抗剂[J].中国中药杂志,2017,42(24):4750-4755. |
| |
| 作者姓名： | 王志国 王丹巧 焦玥 田昕 孙明瑜 |
| |
| 作者单位： | 中国中医科学院 医学实验中心 北京市中医药防治重大疾病基础研究 重点实验室, 北京 100700,中国中医科学院 医学实验中心 北京市中医药防治重大疾病基础研究 重点实验室, 北京 100700,中国中医科学院 医学实验中心 北京市中医药防治重大疾病基础研究 重点实验室, 北京 100700,北京中医药大学, 北京 100029,上海中医药大学 附属曙光医院, 上海 201203 |
| |
| 基金项目： | 国家博士后科学基金特别资助项目（2014T70490）；国家博士后科学基金项目（2013M540426） |
| |
| 摘 要： | 脑卒中是一种急性脑血管疾病,具有发病率高、致残率和致死率高的特点。全球脑卒中防治形势严峻,抗血小板聚集治疗能够有效防治脑卒中。血小板活化因子(PAF)是介导血小板聚集的另一重要介质,在脑卒中病理过程中起着重要作用。近年来,PAF受体拮抗剂在脑卒中防治领域逐渐引起国际关注。该文对PAF受体拮抗剂的分类、作用机制及药物特征进行综述,以期对临床用药及新药研发提供有价值的指导和方向。
|
| 关 键 词： | 脑卒中 血栓 抗血小板药物 血小板活化因子 受体拮抗剂 |
| 收稿时间： | 2017/12/2 0:00:00 |
Stroke, platelet activating factor and receptor antagonists |
| |
| WANG Zhi-guo,WANG Dan-qiao,JIAO Yue,TIAN Xin and SUN Ming-yu.Stroke, platelet activating factor and receptor antagonists[J].China Journal of Chinese Materia Medica,2017,42(24):4750-4755. |
| |
| Authors: | WANG Zhi-guo WANG Dan-qiao JIAO Yue TIAN Xin and SUN Ming-yu |
| |
| Institution: | Beijing Key Laboratory of Basic Research on Prevention and Treatment of Major Diseases by Traditional Chinese Medicine, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China,Beijing Key Laboratory of Basic Research on Prevention and Treatment of Major Diseases by Traditional Chinese Medicine, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China,Beijing Key Laboratory of Basic Research on Prevention and Treatment of Major Diseases by Traditional Chinese Medicine, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China,Beijing University of Traditional Chinese Medicine, Beijing 100029, China and Shuguang Hospital Affiliated, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China |
| |
| Abstract: | Stroke is an acute cerebrovascular disease with high morbidity, disability and mortality. The prevention and treatment conditions for stroke is severe all over the world. Antiplatelet aggregation is an effective treatment. Platelet activation factor (PAF) is another important medium in mediating platelet aggregation, which plays an important role in the pathogenesis of stroke. In recent years, PAF receptor antagonists have attracted international attention in the field of stroke prevention and treatment. In this review, we would summarize the classification, mechanism and drug characteristics of PAF receptor antagonists in order to provide the valuable guidance and direction for clinical medicine and research. |
| |
| Keywords: | stroke thrombus antiplatelet drug platelet activating factor receptor antagonist |
| 本文献已被 CNKI 等数据库收录！ |
|
